STEMCELLS INC Form 8-K February 13, 2014

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

# FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):	February 10, 201
---	------------------

# StemCells, Inc.

(Exact name of registrant as specified in its charter)

Delaware	000-19871	94-3078125
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employe Identification No
7707 Gateway Blvd, Suite 140, Newark, California		94560
(Address of principal executive offices)		(Zip Code)
Registrant s telephone number, including a	rea code:	510.456.4000
	Not Applicable	
Former nam	e or former address, if changed since l	ast report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

I	[]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
I	[]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
I	[]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Ī	[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## Edgar Filing: STEMCELLS INC - Form 8-K

### Top of the Form

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 10, 2014, Dr. Eliseo Salinas resigned from his position as the Company's EVP and Head of Research and Development for personal reasons. His employment termination date will be Friday, February 21, 2014.

# Edgar Filing: STEMCELLS INC - Form 8-K

### Top of the Form

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

StemCells, Inc.

February 13, 2014

By: /s/ Ken Stratton, Attorney-in-Fact

Name: Ken Stratton, Attorney-in-Fact

Title: General Counsel